The findings in this and future studies could help with the development of therapeutic strategies74, 75, 76, because NPM1 mutation is a founder genetic lesion in acute myeloid leukaemia (AML) and an attractive target for intervention76, 77, 78, 79, 80, 81. Here, NPM1 is linked to acute myeloid leukemia.